Next-Generation Antibody Therapeutics Market Report 2026

The next-generation antibody therapeutics market size has grown rapidly in recent years. It will grow from $7.56 billion in 2025 to $8.35 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to growth in monoclonal antibody approvals, increasing cancer prevalence, expansion of biologics manufacturing capacity, rising investment in pharmaceutical r&d, improved regulatory pathways for biologics.

The next-generation antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $12.63 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to advancement in antibody engineering technologies, rising demand for targeted therapies, increasing incidence of chronic and autoimmune diseases, expansion of clinical trials in emerging markets, growing partnerships between biotech and pharma companies. Major trends in the forecast period include expansion of bispecific and multispecific antibody platforms, growing adoption of antibody-drug conjugates in oncology, increased focus on high-affinity and long-acting antibodies, rising clinical pipeline for rare and orphan diseases, shift toward personalized antibody-based therapies.

The rising prevalence of chronic diseases is expected to drive the growth of the next-generation antibody therapeutics market in the coming years. Chronic diseases are conditions that persist for a year or longer and often require ongoing medical care, limit daily activities, or both. Next-generation antibody therapeutics play a critical therapeutic role for individuals with chronic conditions by offering more targeted treatment approaches, thereby improving patient outcomes. For example, in January 2023, projections published by the National Center for Biotechnology Information (NCBI), a U.S.-based National Library of Medicine, indicated that by 2050, the population aged 50 years and older with at least one chronic illness is expected to increase by 99.5%, reaching approximately 142.66 million individuals. Consequently, the growing burden of chronic diseases is fueling the expansion of the next-generation antibody therapeutics market.

Major companies operating in the next-generation antibody therapeutics market are concentrating on technological innovations such as proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology to improve protein identification and characterization, enabling the development of more precise and effective therapies. These advancements are intended to enhance therapeutic performance, lower costs, and address complex diseases with greater accuracy. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a technology that arranges protein molecules into structured assemblies, allowing improved analysis and quantification. It enhances sensitivity and accuracy in protein detection, making it valuable for both research and diagnostic applications. For instance, in January 2024, Infinity Bio, Inc., a U.S.-based biotechnology company, introduced a next-generation antibody profiling platform that leverages MIPSA technology to deliver high-throughput and cost-effective immune response analysis, with the goal of advancing disease understanding and enabling personalized treatment strategies.

In February 2024, AbbVie Inc., a U.S.-based pharmaceutical company, completed the acquisition of ImmunoGen, Inc. for approximately US$10.1 billion. Through this acquisition, AbbVie seeks to strengthen its next-generation antibody therapeutics and oncology pipeline by incorporating ImmunoGen’s folate receptor alpha-targeted antibody-drug conjugate, ELAHERE, which is approved for the treatment of platinum-resistant ovarian cancer, and by expanding its broader portfolio of antibody-drug conjugates across solid tumors and hematologic malignancies. ImmunoGen, Inc. is a U.S.-based biotechnology company specializing in the development of innovative antibody-drug conjugate platforms for oncology.

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., Bristol‑Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE‑Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F‑Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed.

North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created cost and supply chain challenges for the next-generation antibody therapeutics market by increasing prices of imported biologics raw materials, single-use bioprocessing systems, and specialized manufacturing equipment. These impacts are most evident across antibody-drug conjugates and bispecific antibody segments, particularly in regions dependent on cross-border trade such as north america, europe, and asia-pacific. Tariff pressures have led to higher production costs and extended development timelines, especially for small and mid-sized biotech firms. However, tariffs are also encouraging local manufacturing investments, regional supply chain diversification, and long-term capacity building in domestic biologics production.

The next-generation antibody therapeutics market research report is one of a series of new reports that provides next-generation antibody therapeutics market statistics, including next-generation antibody therapeutics industry global market size, regional shares, competitors with a next-generation antibody therapeutics market share, detailed next-generation antibody therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation antibody therapeutics industry. This next-generation antibody therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Next-generation antibody therapeutics are advanced antibody-based medicines that offer enhanced structure, functionality, and therapeutic potential compared to conventional monoclonal antibodies. These therapies are used to address a range of serious medical conditions, including cancer, infectious diseases, and immunological disorders.

The primary types of antibodies in next-generation antibody therapeutics include monoclonal antibodies, polyclonal antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are laboratory-developed proteins designed to bind to specific targets in the body, such as antigens present on the surface of cancer cells. The key therapeutic areas include oncology, autoimmune disorders, infectious diseases, neurodegenerative conditions, and others, and these therapies are utilized by hospitals and clinics, research institutes, pharmaceutical companies, biotechnology firms, and other end users.

The next-generation antibody therapeutics market consists of revenues earned by entities by providing services such as antibody engineering, antibody manufacturing, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation antibody therapeutics market also includes sales of immune checkpoint inhibitors, antibody-targeted nanoparticles, and antibody-mimetic proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.